Cargando…
维奈克拉联合阿扎胞苷治疗不适合标准化疗的新诊断急性髓系白血病疗效分析:单中心数据
OBJECTIVE: To investigate the effectiveness and safety of the VA regimen, which combines venetoclax with azacitidine in the treatment of patients with newly diagnosed acute myeloid leukemia(AML)who are not suitable candidates for conventional chemotherapy. METHODS: In the Department of Hematology at...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669628/ https://www.ncbi.nlm.nih.gov/pubmed/36709196 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.10.005 |
Ejemplares similares
-
维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效:单中心数据
Publicado: (2022) -
维奈克拉联合阿扎胞苷治疗难治复发性急性髓系白血病疗效及安全性分析
Publicado: (2021) -
单中心阿扎胞苷联合维奈克拉和联合HAG方案诱导治疗老年急性髓系白血病的疗效比较
Publicado: (2023) -
维奈克拉联合阿扎胞苷治疗NPM1/IDH1突变急性髓系白血病复发患者获持久分子学缓解1例
Publicado: (2022) -
索拉非尼联合维奈克拉、阿扎胞苷方案诱导治疗FLT3-ITD突变阳性急性髓系白血病12例的疗效及安全性分析
Publicado: (2022)